#
# List of treatments for testing.  Each line is the following format:
#
# Gene\tVariant\tTumorType\tTreatments\tLevel
#

# Test KIT
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505I	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	N505I	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	N505I	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	N505L	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	N505L	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	N505L	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	N505L	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	M541L	Gastrointestinal Stromal Tumor
KIT	M541L	Melanoma
KIT	M541L	Colorectal Cancer
KIT	M541L	Thymic Tumor
KIT	M541C	Gastrointestinal Stromal Tumor
KIT	M541C	Melanoma
KIT	M541C	Colorectal Cancer
KIT	M541C	Thymic Tumor
KIT	Y553N	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	Y553N	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	Y553N	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	Y553N	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	Y553C	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	Y553C	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	Y553C	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	Y553C	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	R643W	Gastrointestinal Stromal Tumor
KIT	R643W	Melanoma
KIT	R643W	Colorectal Cancer
KIT	R643W	Thymic Tumor
KIT	D737N	Gastrointestinal Stromal Tumor
KIT	D737N	Melanoma
KIT	D737N	Colorectal Cancer
KIT	D737N	Thymic Tumor
KIT	C809G	Gastrointestinal Stromal Tumor	1: Regorafenib; 2: Sorafenib; R2: Imatinib; R2: Sunitinib;
KIT	C809G	Melanoma	2: Imatinib; 3B: Regorafenib; 3B: Sorafenib;
KIT	C809G	Colorectal Cancer	3B: Regorafenib; 3B: Sorafenib;
KIT	C809G	Thymic Tumor	2: Sunitinib; 3B: Regorafenib; 3B: Sorafenib;
KIT	K642E	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	K642E	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	K642E	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	K642E	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	K642G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	K642G	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	K642G	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	K642G	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	V654A	Gastrointestinal Stromal Tumor	1: Sunitinib; 1: Regorafenib; R2: Imatinib;
KIT	V654A	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	V654A	Colorectal Cancer	3B: Sunitinib; 3B: Regorafenib;
KIT	V654A	Thymic Tumor	2: Sunitinib; 3B: Regorafenib;
KIT	V654G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib;
KIT	V654G	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	V654G	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	V654G	Thymic Tumor	2: Sunitinib; 3B: Imatinib; 3B: Regorafenib;
KIT	T670I	Gastrointestinal Stromal Tumor	1: Sunitinib; 1: Regorafenib; R2: Imatinib;
KIT	T670I	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib;
KIT	T670I	Colorectal Cancer	3B: Sunitinib; 3B: Regorafenib;
KIT	T670I	Thymic Tumor	2: Sunitinib; 3B: Regorafenib;
KIT	T670C	Gastrointestinal Stromal Tumor
KIT	T670C	Melanoma
KIT	T670C	Colorectal Cancer
KIT	T670C	Thymic Tumor
KIT	D816A	Gastrointestinal Stromal Tumor  3B: Avapritinib;
KIT	D816A	Melanoma	2: Imatinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Avapritinib;
KIT	D816A	Colorectal Cancer 3B: Regorafenib; 3B: Sorafenib;
KIT	D816A	Mastocytosis	3A: Avapritinib;
KIT	D816A	Thymic Tumor	2: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Avapritinib;
MTOR	L2427Q	Renal Clear Cell Carcinoma	3A: Temsirolimus; 4: Everolimus;
PDGFRA	D842I	GIST	2: Imatinib;
PDGFRA	D842I	Thymic Tumor	3B: Imatinib;
PDGFRA	D842V	GIST	R1: Imatinib; 1: Avapritinib; 2: Dasatinib;
PDGFRA	D842V	Thymic Tumor	3B: Avapritinib; 3B: Dasatinib; 3B: Imatinib;
EGFR	A763_Y764insFQEA	NSCLC	2: Afatinib; 2: Erlotinib; 2: Gefitinib; 3A: Poziotinib;
# this one overlaps with A763_Y764insFQEA, but the rule only applies to exact match, so R1 will be used
EGFR	Y764_D770dup	NSCLC	R1: Afatinib; R1: Erlotinib; R1: Gefitinib; 3A: Poziotinib;
# this one does not overlap with A763_Y764insFQEA, so R1 for sure
EGFR	N771delinsSTH	Lung Adenocarcinoma	R1: Afatinib; R1: Erlotinib; R1: Gefitinib; 3A: Poziotinib;

# test cases cover the resistance treatment should overwrite sensitive from alternative allele
ABL1	T315I	Chronic Myelogenous Leukemia	R1: Bosutinib; R1: Dasatinib; R1: Imatinib; R1: Nilotinib; 1: Ponatinib;
ABL1	T315I	Melanoma

ABL1	T315A	Chronic Myelogenous Leukemia	2: Bosutinib; 2: Nilotinib;
ABL1	T315A	Melanoma

ABL1	T315V	Chronic Myelogenous Leukemia
ABL1	T315V	Melanoma

# test few more resistance treatments
PDGFRA	D842V	Gastrointestinal Stromal Tumor	R1: Imatinib; 1: Avapritinib; 2: Dasatinib;
PDGFRA	D842V	Melanoma	3B: Avapritinib; 3B: Dasatinib; 3B: Imatinib;
PDGFRA	D842H	Gastrointestinal Stromal Tumor	2: Imatinib;
PDGFRA	D842H	Melanoma	3B: Imatinib;


# Test Heme
FLT3	Internal Tandem Duplication	AML	1: Gilteritinib; 1: Midostaurin+High Dose Chemotherapy; 3A: Crenolanib; 3A: Quizartinib; 3A: Sorafenib;
FLT3	Internal Tandem Duplication	APLPMLRARA	1: Gilteritinib; 1: Midostaurin+High Dose Chemotherapy; 3A: Crenolanib; 3A: Quizartinib; 3A: Sorafenib;
FLT3	Internal Tandem Duplication	Colorectal Cancer
SF3B1	K700E	AML	4: H3B-8800;
SF3B1	K700E	AMLNOS	4: H3B-8800;
SF3B1	K700E	APLPMLRARA	4: H3B-8800;
SF3B1	K700E	Colorectal Cancer
DNMT3A	P904L	AML
DNMT3A	P904L	APLPMLRARA
DNMT3A	P904L	CMML
DNMT3A	P904L	Colorectal Cancer
ABL1	BCR-ABL1 Fusion	BLL	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLNOS	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLBCRABL1	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	Colorectal Cancer
ABL1	E255K	CML	2: Bosutinib; 2: Dasatinib;
ABL1	E255K	CMLBCRABL1	2: Bosutinib; 2: Dasatinib;
ABL1	E255K	AML
ABL1	E255K	Colorectal Cancer
KMT2	KMT2-MLLT3 Fusion	AML
KMT2	KMT2-MLLT3 Fusion	APLPMLRARA
KMT2	KMT2-MLLT3 Fusion	Colorectal Cacner
PDGFRB	PDGFRB-CSF1R Fusion	CMML	1: Imatinib;
PDGFRB	PDGFRB-CSF1R Fusion	Colorectal Cancer
BRAF	K601E	Colorectal Cancer	3B: Trametinib; 4: PLX8394;
#BRAF	K601E	CMML
ARAF	S214A	HDCN	3A: Cobimetinib; 3A: Sorafenib;
ARAF	S214A	ECD	3A: Cobimetinib; 3A: Sorafenib;
#ARAF	S214A	RDD
ARAF	S214A	Colorectal Cancer	3B: Sorafenib;
TP53	K292T	AML
TP53	K292T	APLPMLRARA
TP53	K292T	Colorectal cancer

# Test solid/liquid propagation
ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	1: Dasatinib; 1: Imatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	1: Bosutinib; 1: Dasatinib; 1: Imatinib; 1: Nilotinib; 3A: Asciminib;
ABL1	BCR-ABL1 Fusion	Acute Myeloid Leukemia
IDH1	R132H	Acute Myeloid Leukemia	1: Ivosidenib;
IDH1	R132H	Glioblastoma	3B: Ivosidenib;
IDH1	R132H	B-Lymphoblastic Leukemia/Lymphoma	3B: Ivosidenib;
IDH1	R132H	Therapy-Related Acute Myeloid Leukemia	1: Ivosidenib;
IDH2	R172K	Acute Myeloid Leukemia	1: Enasidenib;
IDH2	R172K	Melanoma	3B: Enasidenib;
MAP2K1	K57N	Erdheim-Chester Disease	3A: Cobimetinib; 3A: Trametinib;
MAP2K1	K57N	Lung Adenocarcinoma	3A: Cobimetinib; 3A: Trametinib;
MAP2K1	K57N	Glioblastoma	3B: Cobimetinib; 3B: Trametinib;
#MAP2K1	K57N	Diffuse Large B-Cell Lymphoma, NOS
PIK3CA	E545K	Breast Cancer	1: Fulvestrant+Alpelisib; 3A: Copanlisib+Fulvestrant; 3A: GDC-0077;
PIK3CA	E545K	Ovarian Cancer	3B: Copanlisib+Fulvestrant; 3B: Fulvestrant+Alpelisib; 3B: GDC-0077;
#PIK3CA	E545K	Acute Myeloid Leukemia
NRAS	G12C	Breast Cancer	3B: Binimetinib; 3B: Binimetinib+Ribociclib;
#NRAS	G12C	Chronic Myelogenous Leukemia
SF3B1	K625G	Chronic Myelomonocytic Leukemia	4: H3B-8800;
SF3B1	K625G	Breast Cancer

# AMG-510 should only work for KRAS G12C, not alternative allele
# the following tests should be enabled when the liquid propagation is in production also the AGM-510 treatment is in place
KRAS	G12C	Breast Cancer	3B: AMG-510; 4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12D	Breast Cancer	4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12C	NSCLC	3A: AMG-510; 4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12D	NSCLC	4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12C	AML
KRAS	G12D	AML
KRAS	G12C	Leukemia
KRAS	G12D	Leukemia

# Check the Alternative Allele rule
# When we map treatments, we should not map the treatments of alternative alleles. If it applies to all alleles, it should be curated under positional variant
BRAF	V600E	Anaplastic Thyroid Cancer	1: Dabrafenib+Trametinib; 3B: Dabrafenib; 3B: Dabrafenib+Panitumumab+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Encorafenib+Cetuximab+Binimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600K	Anaplastic Thyroid Cancer	2: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600E	Melanoma	1: Dabrafenib; 1: Dabrafenib+Trametinib; 1: Encorafenib+Binimetinib; 1: Trametinib; 1: Vemurafenib; 1: Vemurafenib+Cobimetinib; 3B: Dabrafenib+Panitumumab+Trametinib; 3B: Encorafenib+Cetuximab+Binimetinib;
BRAF	V600K	Melanoma	1: Dabrafenib+Trametinib; 1: Encorafenib+Binimetinib; 1: Trametinib; 1: Vemurafenib+Cobimetinib;
BRAF	V600G	Melanoma	2: Dabrafenib+Trametinib; 2: Encorafenib+Binimetinib; 2: Vemurafenib+Cobimetinib;
BRAF	V600E	NSCLC	1: Dabrafenib+Trametinib; 3B: Dabrafenib; 3B: Dabrafenib+Panitumumab+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Encorafenib+Cetuximab+Binimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600K	NSCLC	3B: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600G	NSCLC	3B: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600K	NSCLC	3B: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600E	Colorectal Cancer   2: Dabrafenib+Panitumumab+Trametinib; 2: Encorafenib+Cetuximab+Binimetinib; 3B: Dabrafenib; 3B: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600K	Colorectal Cancer   3B: Dabrafenib+Trametinib; 3B: Encorafenib+Binimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600E	HCL	2: Vemurafenib;
BRAF	V600K	HCL
AKT1	E17K	Breast Cancer   3A: AZD5363;
AKT1	E17K	NSCLC	3B: AZD5363;
AKT1	E17G	Breast Cancer
FGFR3	Y373C	Bladder Cancer	1: Erdafitinib; 3A: AZD4547; 3A: BGJ398; 3A: Debio1347;
FGFR3	Y373G	Bladder Cancer	4: AZD4547; 4: BGJ398; 4: Debio1347; 4: Erdafitinib;
EGFR	A750P	NSCLC	4: Afatinib; 4: Erlotinib; 4: Gefitinib;
EGFR	A750G	NSCLC
MTOR	E2014K	Bladder Cancer	3A: Everolimus; 4: Temsirolimus;
MTOR	E2014L	Bladder Cancer	4: Everolimus; 4: Temsirolimus;
MTOR	E2014K	NSCLC	3B: Everolimus; 4: Temsirolimus;
ABL1	Y253H	CML	2: Bosutinib; 2: Dasatinib;
ABL1	Y253H	TLL
ABL1	Y253M	CML
BRAF	L597R	Melanoma	3A: Trametinib; 4: PLX8394;
BRAF	L597M	NSCLC	3B: Trametinib; 4: PLX8394;
EGFR	L861Q	NSCLC	1: Afatinib;
EGFR	L861R	NSCLC	3A: Afatinib; 3A: Erlotinib; 3A: Gefitinib;
EGFR	L861M	NSCLC
KRAS	G12C	NSCLC	3A: AMG-510; 4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12C	Melanoma	3B: AMG-510; 4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12A	NSCLC	4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12A	Melanoma	4: Binimetinib; 4: Cobimetinib; 4: Trametinib;
KRAS	G12C	Histiocytosis	3A: Cobimetinib;
KRAS	G12A	Histiocytosis	3A: Cobimetinib;
IDH1	R132H	AML	1: Ivosidenib;
IDH1	R132G	AML	1: Ivosidenib;
